---
title: "Betting On Moderna? This New Defiance ETF Turns The Volume Up 2X"
description: "Defiance ETFs has launched a new 2X leveraged ETF linked to Moderna Inc (NASDAQ:MRNA), named the Defiance Daily Target 2X Long MRNA ETF (NYSE:MRNX). This fund aims to provide traders with amplified da"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275363047.md"
published_at: "2026-02-09T21:08:56.000Z"
---

# Betting On Moderna? This New Defiance ETF Turns The Volume Up 2X

> Defiance ETFs has launched a new 2X leveraged ETF linked to Moderna Inc (NASDAQ:MRNA), named the Defiance Daily Target 2X Long MRNA ETF (NYSE:MRNX). This fund aims to provide traders with amplified daily exposure to Moderna's stock, targeting short-term tactical positioning rather than long-term investment. The ETF is designed for sophisticated investors who understand the risks of leveraged products, as it resets daily and is not meant for extended holding periods. This launch reflects the growing trend of single-stock leveraged ETFs in the market.

As single-stock leveraged ETFs continue to proliferate, **Defiance ETFs** last week added a 2X **Moderna Inc** (NASDAQ:MRNA)-linked fund, the **Defiance Daily Target 2X Long MRNA ETF** (NYSE:MRNX), targeting traders looking for magnified short-term exposure to the biotech giant.

The new ETF aims to deliver two times or 200 percent daily percentage movements of shares for Moderna, a biotechnology company that has gained prominence for its mRNA technology and vaccine capacity. The fund targets short-term tactical positioning rather than long-term investment exposure, reflecting the typical use case for leveraged ETFs.

According to the firm, MRNX enables investors to gain a liquid and exchange-traded vehicle to bet on their bullish, short-term views on Moderna stock, bypassing any direct utilization of derivatives or margin accounts. The fund resets daily and, like all other day leveraged ETFs, is not intended to track twice the stock’s performance over period-long holding periods.

### New ETF Offers Amplified MRNA Exposure

Moderna remains one of Wall Street’s most closely watched names within biotechnology, with its work in mRNA-based therapeutics and vaccines. It gained global recognition during the COVID-19 pandemic for its mRNA vaccine, and continued to expand research in infectious diseases while also pursuing other areas of unmet medical needs. Its technology platform focuses on using messenger RNA to instruct cells to produce proteins that can help prevent or treat disease.

The launch marks continued growth in the single-stock ETF segment, where issuers are increasingly offering leveraged and inverse products linked to individual companies versus broad indexes. These strategies have gained traction among active traders seeking short-term opportunities linked to earnings cycles, sector momentum, or company-specific catalysts.

Defiance ETFs said the fund is intended primarily for sophisticated investors who actively monitor positions and understand the risks associated with leveraged products, including potential volatility and performance divergence over extended holding periods.

With MRNX, the company further extends its suite of leveraged ETFs focused on companies perceived as leaders in emerging technologies, with a specific concentration on biotechnology and life sciences.

*Image: Shutterstock*

### Related Stocks

- [MRNA.US - Moderna](https://longbridge.com/en/quote/MRNA.US.md)
- [MRNX.US - Defiance Daily Target 2X Long MRNA ETF](https://longbridge.com/en/quote/MRNX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Moderna｜10-K：2025 财年营收 19.44 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276485157.md) |
| 美股夜盘异动：莫德纳夜盘跌近 8%，FDA 拒审流感疫苗与分析师下调目标价双重打击 | Moderna 夜盘跌 7.89%；Recursion Pharmaceuticals 夜盘涨 1.56%，成交额达到 2.84 万美元；Viking 治疗夜盘跌 0.87%，成交额达到 1.15 万美元；ImmunityBio 成交额达到 | [Link](https://longbridge.com/en/news/275533451.md) |
| 期权热点｜周四 MRNA 大涨 6%，部分看涨期权飙升 241% | 美东时间 02 月 19 日，Moderna 期权总成交 124309 张，看涨期权占比 84%，看跌期权占比 15%。 | [Link](https://longbridge.com/en/news/276409384.md) |
| 欧盟监管机构支持批准 Moderna 的联合新冠和流感疫苗 | 欧洲药品监管局已建议批准 Moderna 的 mCombriax，这是一种针对 50 岁及以上人群的联合 COVID-19 和流感疫苗。该疫苗采用信使 RNA 技术，在一项涉及 8000 名参与者的研究中，与传统流感疫苗和 Moderna  | [Link](https://longbridge.com/en/news/277190084.md) |
| 美股盘前热门交易：Centrus Energy 盘前跌 8.34%；Moderna 盘前跌 8.32% | Centrus Energy 盘前跌 8.34%；Moderna 盘前跌 8.32%；RenX Enterprises 盘前涨 149.71%；Brenmiller Energy 盘前涨 61.55%；Quince Therapeutics | [Link](https://longbridge.com/en/news/275584253.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.